Former EMA policy on minor use / minor species  (MUMS) / veterinary limited markets

Between 2011 and 2022, the European Medicines Agency (EMA) had a policy on minor use / minor species  (MUMS) / limited markets, to support the availability of veterinary medicines for the treatment of minor animal species and uncommon diseases in major animal species.

The limited market provisions of the Veterinary Medicinal Products Regulation (Regulation (EU) 2019/6) superseded EMA's former MUMS / limited market policy on 28 January 2022. For more information and guidance on the current framework, see Veterinary limited markets.

The former MUMS / limited market policy is available below: 

Applicants for medicines classified as MUMS / limited market under EMA's MUMS / limited market policy benefited from reduced data requirements for marketing authorisation in the following areas, for which superseded scientific guidelines are available:

• Quality
• Safety and residues
• Efficacy
• Immunologicals

EMA published annual reports on the activities carried out under its MUMS / limited market policy. These include requests for MUMS / limited market classification, incentives provided and support to applicants in determining data requirements.